However, the killing effect of monoclonal antibodies such as trastuzumab and pertuzumab on HER2-overexpressing breast cancer cells still depends on the activity of immune cells, and drug resistance due to epitope masking and steric hindrance remains a major difficulty that needs to be addressed appropriately (171). The gene discussed is ERBB2; the disease is breast carcinoma.